Aurobindo Pharma (BSE: 524804; NSE: AUROPHARMA), an Indian pharmaceutical company, headquartered in Hyderabad has unveiled its Q1 FY2024 financial results on 12th August, 2023, highlighting significant achievements in its operations and a notable surge in its revenue streams. Though the revenue is up by 10%, net profit declined by 22.5%
Here’s a detailed look at what the pharmaceutical giant achieved this past quarter.
Aurobindo Pharma Operational Revenue Surges by 9.9%
Aurobindo Pharma’s operational revenue for the April-June quarter stood at ₹6,850.5 crore, marking a 9.9% increase from ₹6,236 crore of the same period in the previous fiscal year. This growth is attributed to strong performance in both the US and Europe formulations and the Active Pharmaceutical Ingredients (APIs) segments.
AUROPHARMA Net Profit Witnesses a 22.5% Dip
Despite an increase in revenue, the net profit saw a decline, dropping by 22.5% to ₹540 crore from the earlier ₹697.6 crore in the corresponding period last year.
Robust Growth in the US and European Markets
The US formulations segment saw an 11.2% year-on-year growth, bolstered by the introduction of 15 new products, including five injectables, and now accounts for 48.2% of the total consolidated revenues. Europe wasn’t far behind with its formulations revenue, which increased by a remarkable 18.6% year-on-year.
API Segment Showcases Strong Performance
The Active Pharmaceutical Ingredients (API) segment recorded a 14% year-on-year growth, contributing ₹1,033 crore, which is roughly 15% of the overall Q1 revenue.
Research & Development Spend
The company invested ₹387.6 crore in Research & Development (R&D) activities, which is 5.7% of the total revenue. This is a slight reduction from the 6.3% spent in the previous quarter.
Achievements in the Drug Application Sphere
Aurobindo Pharma was busy on the regulatory front. The company filed 12 Abbreviated New Drug Applications (ANDAs), which included an injectable product with the US Food and Drug Administration (FDA). In addition to this, they received the green light for 19 ANDAs during this quarter.
Restructuring and Personnel Changes
A significant announcement came about the company’s decision to reevaluate the business structure of Eugia Pharma Specialities Limited, their wholly-owned subsidiary. The Board also acknowledged the resignation of Dr. M. Sivakumaran, the whole-time Director of the company. He will step down from his role on August 24, 2023.
Statements from the Leadership
K. Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma, expressed optimism about the company’s future, pointing to strong top-line growth and improved performance across their key markets. He emphasized the company’s commitment to long-term growth and delivering value to shareholders.
Market Reaction
Aurobindo Pharma shares settled at ₹863.05 on August 11, marking a 1.09% decrease. It will be interesting to see how markets react on Monday opening.
Earning Reports of other Pharma Companies:
- Cipla Q1 Fy 2024 Earning Report – Profit or Loss?
- Syngene International Q1 FY 2024 Earnings Report – Profit of Loss
In my opinion, Q1 FY2024 results of Aurobindo Pharma signify a mixed bag, with increased revenue growth but a dip in net profits. With a strong focus on expanding their product line and exploring new markets, the pharmaceutical behemoth looks set for exciting times ahead.
What did we learn?
- 1 Aurobindo Pharma Operational Revenue Surges by 9.9%
- 2 AUROPHARMA Net Profit Witnesses a 22.5% Dip
- 3 Robust Growth in the US and European Markets
- 4 API Segment Showcases Strong Performance
- 5 Research & Development Spend
- 6 Achievements in the Drug Application Sphere
- 7 Restructuring and Personnel Changes
- 8 Statements from the Leadership
- 9 Market Reaction
Twitter
